<DOC>
	<DOC>NCT00511771</DOC>
	<brief_summary>To provide tegaserod to eligible women adult patients who did not have satisfactory improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) symptoms with other available treatment(s) and / or patients who had satisfactory improvement of their symptoms with prior tegaserod treatment for IBS-C or CIC.</brief_summary>
	<brief_title>A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>1. For patients with IBSC: Women of 1854 years of age with IBSC according to the Rome III criteria. 2. For patients with Chronic Idiopathic Constipation: Women of 1854 years of age with CIC according to the Rome III criteria . 3. Patients who did not have satisfactory symptom improvement of their IBSC or CIC symptoms with other available treatment(s) and / or patients who had satisfactory improvement of their symptoms with prior tegaserod treatment for IBSC or CIC. Satisfactory symptom improvement will be assessed by the patient. 4. Patients signed the informed consent 1. History of or current diagnosis of cardiovascular ischemic disease (e.g., angina pectoris, myocardial infarction, transient ischemic attack or stroke and including findings suggestive of ischemia on an ECG such as changes in ST segment and T waves, and / or Q wave) 2. Patients who have uninvestigated symptoms suggestive of a cardiovascular ischaemic disease such as chest pain or chest discomfort, shortness of breath, sudden onset of weakness of the arms or the legs, difficult talking or loss of sensation etc 3. Presence of any cardiovascular risk factors according to the NIH guideline [NIH Publication No. 013670] (such as hypertension, hyperlipidemia, diabetes mellitus, active smoking, obesity and family history of premature coronary heart disease) as assessed by the investigator 4. Clinical evidence of significant (as judged by the Investigator) respiratory, cardiovascular, renal, hepaticbiliary, endocrine, psychiatric or neurologic diseases or presence of abdominal adhesions 5. History of or current eating disorder such as anorexia or bulimia or compulsory overeating. 6. Uncompensated depression or anxiety or suicidal ideation or behavior. 7. Diagnosis of megarectum or colon, a history of intestinal obstruction, congenital anorectal malformation, clinically significant rectocele, or any evidence of intestinal structural abnormality including gastrointestinal resection that affected bowel transit or any evidence of intestinal carcinoma, of inflammatory bowel disease or of alarm symptoms such as weight loss, rectal bleeding, or anemia 8. Evidence of cathartic colon or a history of drug (including laxative) or alcohol abuse, that in the Investigator's opinion, the patient is likely to continue to abuse these substances during the tIND program period 9. Pregnant women or breastfeeding women; fertile women who are not currently practicing medically approved method of contraception 10. Participating in other investigational studies concurrently or within 1 month prior to entering this tIND program 11. Hypersensitive to tegaserod or to any of the excipients 12. Patients who had tolerability or safety concerns with prior use of tegaserod.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Tegaserod, treatment IND, irritable bowel syndrome with constipation, IBS-C, chronic idiopathic constipation, CIC, chronic constipation, CC</keyword>
</DOC>